Introduction: Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials. gov. Methods: Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with cognitive, functional, and behavioral alterations [1, 2] . AD is age related and is becoming markedly more common with the aging of the world's population. It is estimated that by 2050, one in every 85 people will be living with AD [3] . Nearly eightfold as many people have preclinical AD as have symptomatic AD and are at risk for progressing to manifest disease [4] . Disease-modifying therapies (DMTs) that will prevent or delay the onset or slow the progression of AD are urgently needed. A modest 1-year delay in onset by 2020 would result in there being 9.2 million fewer cases in 2050 [3] . Similarly, medications to effectively improve cognition or ameliorate neuropsychiatric symptoms of patients in the symptomatic phases of AD are needed to improve memory and behavior [5] .
In this update of our annual review of the AD drug development pipeline, we provide a summary of the current state of progress in developing new therapies for AD [6, 7] . We discuss each phase of the AD pipeline (I, II, and III) and describe DMTs, cognitive-enhancing agents, and treatments for behavioral disturbances in AD that are in development. We note the use of biomarkers in clinical trials. We describe evolving targets of the agents in the pipeline. We discuss trial infrastructure changes that may accelerate clinical trials and drug development. Our goal is to provide insight into the drug development process and to help drug developers and clinical trialists learn from the current pipeline experience.
Methods
This annual review is based on clinical trial activity as recorded in clinicaltrials.gov, a comprehensive US government database. The US law requires that all clinical trials conducted in the United States be registered on the site. The "common rule" governing clinicaltrials.gov was recently updated and mandated registration of all trials from sponsors with an Investigational New Drug or Investigational New Device [8, 9] . Trials must be registered within 21 days of the enrollment of the first trial participant. Results for the primary outcome measures must be submitted to clincaltrials.gov within 12 months of completion of final data collection. Compliance with trial registration is high [10] [11] [12] ; compliance with results reporting is lower [13] . Clinicaltrials.gov can be regarded as a comprehensive and valid data source for the study of clinical trials conducted in the United States. Not all non-US trials are registered on clinicaltrials.gov-especially phase I trials-and our findings may underrepresent the agents populating global phase I efforts.
Results reported here are based on trials registered on clinicaltrials.gov as of January 30, 2018 . We include all trials of all agents in phase I, II, and III; some trials are presented as I/II or II/III in the database, and we use that nomenclature in the review. In our trial database, we entered the trial title; beginning date; projected end date; calculated duration; planned enrollment number; number of arms of the study (usually a placebo arm and one or more treatment arms with different doses); whether a biomarker was described; subject characteristics; and sponsorship by a biopharma company, National Institutes of Health, academic medical center, "other" entity such as a consortium or a philanthropic organization, or a combination of these sponsors. Using the clinicaltrials.gov classification, we included trials that were recruiting, active but not recruiting (e.g., trials that have completed recruiting and are continuing with the exposure portion of the trial), enrolling by invitation, and not yet recruiting. We did not include trials listed as completed, terminated, suspended, unknown, or withdrawn because information on these trials is often incomplete. We included all pharmacologic trials listed in the database; we did not include trials of nonpharmacologic therapeutic approaches such as devices, cognitive therapies, caregiver interventions, supplements, and medical foods. We did not include trials of biomarkers although we noted whether biomarkers were used in the trials of interest.
Drug targets and mechanism of action (MOA) of treatments are important aspects of this review. MOA was determined from the information on clinicaltrials.gov or from a comprehensive search of the literature. In a few cases, the mechanism is undisclosed and could not be identified in the literature, and we note these agents as having an "unknown" MOA. We grouped the mechanisms into symptomatic agents or DMTs. We divided the symptomatic agents into those that are putative cognitive-enhancing agents or those that address neuropsychiatric and behavioral symptoms. DMTs were divided into those targeting amyloidrelated mechanisms, those that have tau-related MOAs, and those with "other" mechanisms such as neuroprotective agents, anti-inflammatory drugs, growth factors, or agents with metabolic effects. Stem cell therapies were included in the "other" category. Some agents have multiple effects and might be expected to have symptomatic and diseasemodifying properties. We classified these drugs as symptomatic or DMTs based on the trial design. Agents in large, long (12-24 months) trials with biomarker outcomes are listed as DMTs. Those in smaller, shorter (3-6 months) trials with cognitive or behavioral outcomes and no biomarkers are listed as symptomatic. Agents could change classification as more information accrues. Fig. 1 provides an overview of all agents identified in the current AD pipeline. The main circles of the figure reveal the stage of development (I, II, and III), the colors pertain to the MOA of the agent, and the shape denotes the population in which the agent is being tested (normal volunteers, cognitively normal at-risk individuals, prodromal AD, and AD dementia).
Results

Overview
In total, there are 112 agents in the pipeline as shown on clinicaltrials.gov. We identified 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. Review of the MOAs of pipeline agents showed that 63% are DMTs, 22% are symptomatic cognitive enhancers, 12% are symptomatic agents addressing neuropsychiatric and behavioral changes, and 3% have undisclosed MOAs.
Phase III
Phase III of the 2018 AD pipeline has 26 agents; 17 DMTs, one cognitive-enhancing agent, and eight drugs for behavioral symptoms (Fig. 1, Table 1 ). Among the DMTs, 14 addressed amyloid targets, one involved a tau-related target, one involved neuroprotection, and one had a metabolic MOA. The DMTs include six immunotherapies (all addressing amyloid). Of the DMTs, two are repurposed agents approved for use in another indication (insulin, albumin plus immunoglobulin). Of the drugs with amyloid targets, there were five Beta-site Amyloid precursor protein Cleavage Enzyme inhibitors, six immunotherapies, and three antiaggregation agents. Fig. 2 shows the MOAs of agents in phase III.
There is a movement toward treating patients with milder forms of AD including cognitively normal individuals with evidence of amyloid pathology (by cerebrospinal fluid [CSF] measures or amyloid positron emission tomography [PET]) or who have genetic profiles that place them at high risk for developing AD (Table 2) . In phase III, there were six prevention trials enrolling cognitively normal participants. There were 12 trials of patients with prodromal AD/mild cognitive impairment (MCI) or prodromal/mild AD; 14 trials of patients with mild-moderate AD; and three trials of patients with mild-moderate/severe AD.
Phase III trials involved a mean of 860 participants and had a mean duration of 1841 days or 263 weeks (including the recruitment and the treatment period). DMT trials were longer than trials of agents with other MOAs (2139 days or 306 weeks; 121 treatment weeks) and larger-including an average of 1066 participants. The mean duration of cognitive enhancer trials was 914 days or 131 weeks (26 treatment weeks), and they included an average of 600 participants. Trials of drugs for behavioral symptoms average 1119 days or 160 weeks (15 treatment weeks) and included a mean of 314 patients. For DMTs, the average duration of treatment exposure is 121 weeks; the mean period from trial initiation to primary completion date (final data collection date for primary outcome measure) is 239 weeks. This indicates that 118 weeks-nearly equal to the treatment period-is the average anticipated recruitment time. When examined by trial population, prevention trials are 420 weeks in duration; trials for patients with MCI/prodromal/ prodromal-mild AD are 289 weeks in duration; and trials for patients mild-moderate AD are 235 weeks in duration. Planned recruitment periods for these three types of trials are 164, 161, and 116 weeks, respectively.
Phase II
In 2018, there are 75 trials involving 63 agents in phase II of the AD pipeline (Table 3) . Sixteen trials involved patients with prodromal or prodromal and mild AD, 28 were trials for mild-moderate AD, one included patients with MCI and mild-moderate AD, one was a prevention trial, one included patients with MCI or healthy volunteers, and one trial was for severe AD. Of the symptomatic agent trials, one was for preclinical AD, seven were for prodromal mild AD, 16 were for mild-moderate AD, and three were for mildmoderate or severe AD. Of the 63 agents, there were 36 DMTs, 21 cognitiveenhancing agents, five drugs for behavioral symptoms, and one agent with an unknown MOA ( Fig. 1 ; Table 3 ). Among the DMTs, 18 involved amyloid targets, nine addressed taurelated targets, one had a mechanism relevant to both amyloid-and tau-related targets, and eight had other MOAs (e.g., neuroprotection, metabolic, or anti-inflammatory). The DMTs include 11 immunotherapies (six addressing amyloid and five addressing tau). Of the DMTs, 12 are repurposed agents approved for use in another indication. There are eight trials involving stem cell therapies.
Of the drugs with amyloid targets, there were three Betasite Amyloid percursor protein Cleavage Enzyme inhibitors, six immunotherapies, and two antiaggregation agents. Four agents involved antiaggregation and neuroprotection, and three agents were antiaggregation, neuroprotective, and metabolic agents. Fig. 3 shows the MOAs of agents in phase II.
Phase II trials are shorter in duration and smaller in terms of participant number than phase III trials: Phase II trials had a mean duration of 1221 days or 174 weeks (recruitment plus exposure period) and included an average of 156 participants in each trial. The average treatment period is 39 weeks.
Phase I
Phase I first-in-human trials are generally conducted in healthy volunteers and sometimes include a cohort of healthy elderly to begin to assess whether age affects the metabolism or excretion of the test agent. In some cases, phase I/IIa trials assess preliminary efficacy in patients HEART, Health Evaluation of African Americans Using RAS Therapy; NIA, National Institute on Aging; PET, positron emission tomography. Fig. 1; Table 4 ), five were immunotherapies directed at amyloid-related targets, four had tau-related MOAs, one addressed both amyloid and tau targets, and seven had other mechanisms (e.g., neuroprotection, metabolic, regenerative, or anti-inflammatory). The MOA was not identified for two agents.
Phase I trials had an average duration of 982 days or 140 weeks (recruitment and treatment period) and included a mean number of 73 participants in each trial.
Trial sponsors
Across all trials, 56.6% are sponsored by the biopharma industry, 31.6% by Academic Medical Centers (with funding from National Institutes of Health, industry, or other entities), and 8.8% by others. Table 5 shows the sponsor of agents is different by trial phases. Table 6 shows the biomarkers used as outcome measures in current phase II and phase III AD clinical trials as described in the federal website; not all trial descriptions in clinicaltrials.gov note if biomarkers are included in the trial.
Biomarkers
AD biomarkers served as secondary outcomes in 18 phase III DMT trials and 20 phase II DMT trials. The most common biomarkers used were CSF amyloid, CSF tau, volumetric magnetic resonance imaging, and amyloid PET. One study reported using tau PET as a secondary outcome.
Amyloid biomarkers can be used to establish the presence of amyloid abnormalities and support the diagnosis of AD. Of the 25 phase III DMT trials, five trials used amyloid-PET as an entry criterion, two used CSF-amyloid, and seven used either amyloid-PET or CSF-amyloid. Ten out of 38 phase II DMT trials used amyloid-PET as an entry criterion, five used CSF-amyloid, and two used either amyloid-PET or CSF-amyloid. Eleven DMT trials in phase III and 21 in Table 3 Agents currently in phase II of Alzheimer's disease drug development (as of January 30, phase II did not require biomarker confirmation of AD for trial entry.
Comparison to 2017 pipeline
Compared with the 2017 pipeline, there are four new agents in phase III (AXS-05, octohydroaminoacridine succinate, escitalopram, and zolpidem), 14 in phase II (BIIB092, deferiprone, DHP1401, GV1001, ID1201, IONIS MAPTRx, LM11A-31-BHS, LY3002813, MLC901, MP-101, montelukast, VX-745, RO7105705, and rotigotine), and eight in phase I (NDX-1017, salsalate, vorinostat, BIIB076, JNJ-63733657, NP001, NPT088, and AGN-242071). Only one of the four new agents in phase III, (octohydroaminoacridine succinate) was previously present in phase II. Of the new agents in phase II, three of the 14 were previously noted in phase I (LY3002813, RO7105705, and VX-745). There are seven repurposed agents in phase III and 24 in phase II of the AD pipeline.
Eight agents listed in phase III in 2017 [7] failed in clinical trials as of January 30, 2018. These included the 5-HT6 inhibitors idalopirdine and intepirdine [17] . Three trials studying solanezumab (EXPEDITION studies) in prodromal/mild AD have been terminated as the study's primary end point was not met. The TOMMORROW studies (TOMM40301 and 303) studying pioglitazone were terminated in early 2018. Other trials failing to meet their primary outcomes included AC-1204, aripiprazole, MK-8931, nilvadipine and azeliragon. Two phase III trials for brexpiprazole as treatment for agitation in AD have completed and a third phase III trial is planned to begin in 2018.
Six agents were listed in phase II in 2017 and are not listed in any phase in 2018 and are no longer in development at this time (they could re-enter development). Trials of four agents were completed in 2017 and are not listed in the 2018 pipeline: BI409306, adenosine triphosphate, PQ912, and T-817MA. The trial status for NewGam 10% intravenous immunoglobulin changed to "unknown" because it has not been updated for more than 2 years on clinicaltrials.gov. Trials for the following five agents in phase I in 2017 were either completed or terminated and are not listed in the 2018 pipeline: BPN14770, PF-06751979, NGP 555, HTL0009936, and LY2599666.
Discussion
The Food and Drug Administration approved 46 new drugs (not including new doses, new formulations, or combinations of existing agents) in 2017. Six agents were approved for central nervous system disorders: edaravone for amyotrophic lateral sclerosis, cerliponase alfa for Batten disease, valbenazine for tardive dyskinesia, deutetrabenazine for chorea associated with Huntington's disease, ocrelizumab for relapsing-remitting and primary progressive multiple sclerosis, and safinamide for patients with Parkinson's disease experiencing "off" episodes (https://fda.gov/drugs/ DevelopmentApprovalProcess). Three of these agents are DMTs (edaravone, cerliponase alfa, and ocrelizumab), and three are symptomatic therapies for amelioration of motor disorders. There were no new drug [5] .
Review of the 2018 AD drug development pipeline shows that most agents have MOAs directed at disease modification (63% across all phases); 23% are cognitive-enhancing agents, and 12% are drugs directed at controlling neuropsychiatric symptoms (three agents have undisclosed MOAs). A few new agents have entered the pipeline when compared with the 2017 review [7] : there are eight new agents in phase I, 14 in phase II, and four in phase III. Several agents have exited the pipeline including: five in phase I, five in phase II, and eight in phase III.
5-hyroxytryptamine-6 receptor antagonists have represented a substantial segment of the AD drug development pipeline with several agents exploring this cognitive enhancing mechanism. SAM-531 (also PF-052-12365) was assessed in a clinical trial of patients with mild-moderate AD not on therapy with memantine or a cholinesterase inhibitor. The trial was interrupted after an interim analysis suggested that all doses in the trial were futile. SB742457 (intepirdine) had evidence of efficacy in a phase II clinical trial [18] but failed to meet primary outcomes in a more recent phase III trial [19] . Similarly, LU-AE-58054 (idalopirdine) achieved a significant benefit on the Alzheimer's Disease Assessment Scale-Cognitive Subscale [20] in phase II but failed to meet its primary outcomes in three phase III trials [17] . Other agents in this class are currently in trials (Suvn-502) or have shown efficacy in preclinical models (PRX-07034Z) [21] . Although recent trials have not demonstrated a drug-placebo difference with 5-HT6 antagonists, unresolved issues regarding the diagnosis of AD in trials not requiring biomarker confirmation, failure of decline of placebo groups in some trials, recruitment of atypical forms of AD (due to exclusion of standard of care with memantine and cholinesterase inhibitors), and dose preclude definitive conclusions about efficacy of this mechanism based on the existing trials.
Phosphodiesterases (PDEs) comprise a group of 11 families of enzymes that regulate cyclic adenosine monophosphate and cyclic guanosine monophosphate and are involved in neuroplasticity and memory consolidation [22] [23] [24] [25] . Several PDE inhibitors have been assessed in clinical trials of AD or MCI [26] , and there are currently three PDE inhibitors in phase I and three in phase II. Three of the agents are PDE9 inhibitors, two are PDE 4 inhibitors, and 1 is a PDE 3 inhibitor. Trial outcomes will determine if PDE inhibitors produce cognitive benefit, if inhibition of one of the enzymes is more effective, and what population of patients is more benefited by treatment.
Biomarkers are important for the develeopment of both symptomatic and disease-modifying drugs. The use of biomarkers has become widespread in trials of DMTs, but biomarkers for symptomatic agents are more unusual. PDE9 inhibitors reduce CSF cyclic guanosine monophosphate, a second messenger that activates intracellular protein kinases. Measures of cyclic guanosine monophosphate have been used as a translational biomarker to establish target engagement and dose-response relationships in both humans and nonhuman primates [27, 28] .
An increasing number of agents are directed at tau-related targets. Neurofibillary tangles, consisting of aggregates of phosphorylated microtubule-associated tau protein, are one of two major pathological hallmarks of AD [1, 2, 29] . Seminal clinicopathological correlation studies conducted by Braak and Braak [30] , demonstrating that neurofibrillary tangle burden more closely correlate with cognitive decline than amyloid plaque load, indicate that agents directed against aberrant tau protein could serve as important anti-AD agents. Normal tau protein goes through multiple biological transformations in AD, and strategies to target tau are diverse. Fig. 4 depicts tau's role in AD pathogenesis and shows the purported MOA of candidate therapies directed at tau biology.
Tau remains an important but largely untested target for disease modification in AD. The first anti-tau programs were directed at reducing tau aggregation. The preliminary results of these studies were largely disappointing, and agents directed against tau aggregation are being re-evaluated [31] . More recently, immunotherapy strategies have achieved ascendency in the pipeline with seven tau immunotherapies entering phase I or II testing. Among the unknowns for tau immunotherapy programs are: (1) which is the most appropriate tau epitope to target, (2) what site of activity is required for effectiveness (intraneuronal vs. extracellular), and (3) what level of target engagement is required for efficacy [32] . The emergence of tau radioligands detectable by PET may provide key insights into these questions [33] ; this technology remains expensive, has limited availability, and understanding of its interpretation is evolving.
A concerning observation derived from this AD pipeline review is the lack of agents targeting the moderate to advanced stages of AD. Only 26 trials permit inclusion of participants with scores of 14 or less, and only 12 include participants with scores of 10 or less. Together, these studies intend to enroll only 1720 participants. With over 15 million people affected by AD dementia worldwide [34] , there is an urgent need to develop more effective symptomatic treatments for moderate to advanced stage disease. The paucity of agents directed at this population represents a significant weakness of the AD drug development pipeline.
A challenge for AD drug development is the lack of surrogate biomarkers. Surrogate markers-measures of disease that can be substituted for a clinical end point (i.e., hemoglobin A1c in diabetes)-predict clinical outcomes and accelerate drug development [35] . In the current AD landscape, there are few biomarkers and no accepted surrogate markers. The primary utility of existing AD biomarkers is to improve diagnostic accuracy [36] , and these have been incorporated into current research criteria [37] [38] [39] . Previous research shows that misdiagnose rates in AD clinical trials can exceed 20% [40] and could contribute importantly to trial failure. Diagnostic verification is particularly important in trials of DMTs. Review of the 2018 pipeline reveals that a surprisingly low percentage of trials of DMTs require diagnostic biomarkers for entry or as secondary outcomes. The development and use of biomarkers for AD clinical trials remain a crucial unmet goal for the field.
Successful drug development requires effective recruitment of clinical trial participants and efficient execution of clinical trials in addition to drugs that are produced by rigorous disciplined drug development processes. Challenges of recruitment have become especially acute as prevention trials have become more numerous. Participants are cognitively normal, are not health-care seeking, and may not know their risk status. There are currently several efforts in the AD drug development arena that address these critical issues. Online registries are increasingly used to identify and educate possible trial participants. These registries vary in nature, with some collecting a minimum of information (age, interest in trials) and others collecting extensive cognitive, clinical, and demographic information [41, 42] . The over-arching purpose of these registries is to identify interested individuals that can be assessed for appropriateness for clinical trials and enlist them if they have the prespecified biomarker profile required for trial participation. Optimizing the use of registries to enhance trial recruitment will be among the important lessons from studying the current registries.
Clinical trial efficiency can be improved with more rapid clinical trial site start up (facility review, budget acceptance, and so on), pre-certified raters, use of a single institutional review board, and rapid recruitment of appropriate participants. Addressing each of these aspects of efficient trial site function can help accelerate clinical trial execution and drug development. In the United States, the Global Alzheimer Platform, the National Institutes of Health, the Alzheimer's Association TrialMatch program, the Alzheimer's Clinical Trial Consortium, and other initiatives are striving to improve trial efficiency [41, 43] . In Europe, the European Prevention of Alzheimer's Dementia program is part of the Innovative Medicines Initiative and is addressing many of the same issues, especially as they apply to phase II clinical trials [44] .
Clinicaltrials.gov has shortcomings that are important to recognize when considering the data presented here. The information provided may not represent the entire universe of AD drug development: not all phase I trials, especially those conducted outside the United States, may be registered in the database and our phase I data may underestimate the number of phase I candidates. Trials are required to be registered within 21 days of entering the first patient into the trial [9] , but not all sponsors may meet this deadline. The Food and Drug Administration Modernization Act requires all trials to be registered, and the International Committee of Medical Journal Editors requires trials to be registered to be eligible for publication [45] ; recent reviews show a high rate of compliance with the registration rules [10] [11] [12] . The clinicaltrials.gov database is the most comprehensive of any existing trial database and provides credible data for drawing conclusions about AD drug development. We stopped entering new data into our database at a time that allowed submission, peer review, and publication; the data presented are a few months out-of-date (data collection stopped on January 30, 2018) .
This review of the 2018 AD drug development pipeline demonstrates the continuing commitment of the scientific community, pharmaceutical industry, and regulatory agencies to develop new drugs of AD. Trends evidenced in the 2018 pipeline include more trials in preclinical and prodromal populations and greater use of biomarkers to support the diagnosis of AD. Every trial is a learning opportunity and informs the drug development process. Success depends on establishing targets critical to the disease process, developing efficacious agents, and conducting trials rigorously.
